Tech Talk: Quality Metrics, Part 2 What Gets Measured Gets Done

At NSF we’re really passionate about two things. > We do our best to our best to ensure our clients continue to supply patients with the products they need. > We help you to prepare for the future, not for a world that no longer exists. We specialize in helping you become resilient so you can prepare for disruptions, recover from shocks and stresses, and bounce back, revitalized from unplanned disruptive events.

Spotlight

BioBots

BioBots is building tools to design and engineer life. Our goals are to cure disease, eliminate the organ waiting list, reverse climate change, and live on other planets. Our first products are 3D bioprinters, software, and bioinks that print 3D living tissues one layer at a time.

OTHER WHITEPAPERS
news image

New Diagnostic Approaches for Undiagnosed Rare Genetic Diseases

whitePaper | April 16, 2020

Accurate diagnosis is the cornerstone of medicine; it is essential for informed care and promoting patient and family well-being. However, families with a rare genetic disease (RGD) often spend more than five years on a diagnostic odyssey of specialist visits and invasive testing that is lengthy, costly, and often futile, as 50% of patients do not receive a molecular diagnosis.

Read More
news image

Your Ultimate Guide to CMC Testing Support for Gene and Cell Therapy

whitePaper | December 6, 2022

The development of Advanced Therapy Medicinal Products such as gene and cell therapy products, has made significant progress in the treatment of many diseases, including cancer, genetic, and autoimmune disorders.

Read More
news image

Gene and cell therapy analytical and development methods

whitePaper | April 20, 2023

In the three decades that have passed since the approval of the first gene therapy in 1990, these revolutionary medicines have changed the lives of patients all over the world1.

Read More
news image

Leveraging innovations in plasmid manufacturing to bring advanced therapies to market

whitePaper | December 13, 2022

The global demand for plasmid DNA has increased dramatically in recent years, fueled by a surge in the clinical development of next-generation cell and gene therapy products and more recently by the success of COVID-19 vaccines.

Read More
news image

Covid-19 Vaccine Distribution System

whitePaper | April 14, 2021

Delivering Covid-19 vaccines to 7.8 billion people is a daunting challenge that will stretch supply chains past their limits. Even if all the needed doses were ready today, vaccine manufacturers still must find solutions to deliver multiple doses of those vaccines to most people on the planet. To read more, please download this free white paper.

Read More
news image

A REVIEW OF THE RESEARCH TRENDS AND DEVELOPMENTS

whitePaper | May 9, 2022

In the last decade, there has been an encouraging shift in research, clinical development, and commercial activity to exploit the many biological roles of ribonucleic acid (RNA) for use in medicine.

Read More

Spotlight

BioBots

BioBots is building tools to design and engineer life. Our goals are to cure disease, eliminate the organ waiting list, reverse climate change, and live on other planets. Our first products are 3D bioprinters, software, and bioinks that print 3D living tissues one layer at a time.

Events